Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results  And Clinical Program Updates   Conference Call and Webcast Today at 4:30 p.m. ET   NEW YORK – December 28, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and…

Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020

Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time   NEW YORK – December 22, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the…

Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co.

Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co.   NEW YORK – December 21, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s…

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome   Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in…